<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04126330</url>
  </required_header>
  <id_info>
    <org_study_id>Provita19</org_study_id>
    <nct_id>NCT04126330</nct_id>
  </id_info>
  <brief_title>Effect of Omega-3 and Probiotic Dietary Supplements on Elevated High Sensitivity C-reactive Protein (Hs-CRP) as a Marker of Low-grade Inflammation</brief_title>
  <official_title>Effect of Omega-3 and Probiotic Dietary Supplements on Elevated High Sensitivity C-reactive Protein (Hs-CRP) as a Marker of Low-grade Inflammation: Targeting Inflammation and Intestinal Barrier Function in the Elderly and Obese</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Örebro University, Sweden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Hohenheim</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Örebro University, Sweden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study objectives:&#xD;
&#xD;
      Immunity, Inflammation, and Brain Function To determine the effect of supplements with&#xD;
      probiotics, Omega-3 and Vitamin D on the inflammatory marker highly sensitive CRP (primary&#xD;
      outcome), markers of inflammation (secondary outcome), and gastrointestinal barrier function&#xD;
      (secondary outcome) in elderly and obese cohorts that exhibit elevated inflammation at&#xD;
      baseline.&#xD;
&#xD;
      Mobility To determine the effect of supplements with probiotics, Omega-3 and Vitamin D on&#xD;
      joints, bones, and muscles by means of the WOMAC questionnaire, sit/stand test (muscle&#xD;
      function) and CTX-I (cartilage degradation) as secondary endpoints in elderly and obese&#xD;
      cohorts that exhibit elevated inflammation at baseline.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 11, 2019</start_date>
  <completion_date type="Actual">December 15, 2020</completion_date>
  <primary_completion_date type="Actual">May 15, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>proof-of-concept, randomized double-blinded placebo-controlled parallel study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>hs-CRP</measure>
    <time_frame>baseline, 4 weeks (mid-study), 8 weeks (study end)</time_frame>
    <description>Decrease in overall body inflammation measured by at least 15% reduction in hs-CRP levels in blood</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">176</enrollment>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>Probiotics and Omega-3/vitamin D Supplements- Elderly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo- Elderly</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Probiotics and Omega-3/vitamin D Supplements- Obese</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo- Obese</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotic, Omega-3, Vitamin D supplement</intervention_name>
    <description>The first supplement we would like to assess is named VNP and is composed by Omega-3 Active and vitamin D. It contains a total of 1100 mg fish oils: 640 mg Omega-3 and with 300 mg eicosapentaenoic acid (EPA), 220 mg docosahexaenoic acid (DHA) plus 200 IU Vitamin D per daily dose (2 capsules).&#xD;
The second supplement we investigate is four-strain probiotics combination based on the commercially available formulation HOWARU® by DuPont; two capsules containing 10 billion CFU total (supplied by Pfizer but manufactured by Danisco, DuPont). The probiotic specific composition, contains equal amounts of each strain per capsule (1.25 x 109 CFU each): Bifidobacterium lactis Bi-07, Lactobacillus paracasei Lpc-37, Lactobacillus acidophilus NCFM, Bifidobacterium lactis Bl-04. One capsule contains 5 billion CFU (Swedish milliards).</description>
    <arm_group_label>Probiotics and Omega-3/vitamin D Supplements- Elderly</arm_group_label>
    <arm_group_label>Probiotics and Omega-3/vitamin D Supplements- Obese</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo generated for probiotic and omega-3/vitamin D supplements</description>
    <arm_group_label>Placebo- Elderly</arm_group_label>
    <arm_group_label>Placebo- Obese</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  65-80 years old for elderly arms&#xD;
&#xD;
          -  25-65 years old for obese arms&#xD;
&#xD;
          -  screening hs-CRP of 1.5-6 mg/L for elderly&#xD;
&#xD;
          -  screening hs-CRP of 2-10 mg/L for obese&#xD;
&#xD;
          -  BMI 18.5-27 for elderly&#xD;
&#xD;
          -  BMI 28-40 for obese&#xD;
&#xD;
          -  Signed informed consent prior to any study related procedures&#xD;
&#xD;
          -  Prospect to start the study the latest 6 weeks after the screening visit although&#xD;
             preferably as soon as they receive the screening results&#xD;
&#xD;
          -  Willing to abstain from regular consumption of probiotic supplements, products&#xD;
             containing probiotic bacteria&#xD;
&#xD;
          -  Willing to abstain from regular consumption of medication known to alter&#xD;
             gastrointestinal functions for at least 4 weeks prior to the time of the study&#xD;
             inclusion&#xD;
&#xD;
          -  Willing to fast at least 5 hours during the sugar-permeability-test and receive a&#xD;
             standardised breakfast (e.g. Cereal bar) or other standardised meal&#xD;
&#xD;
          -  Accepting to drink at least 1.5 litres of provided water in one day, during the two&#xD;
             time points where the sugar test is performed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of type 1 and/or type 2 diabetes&#xD;
&#xD;
          2. Current or within 4 weeks use of probiotic supplement prior to inclusion&#xD;
&#xD;
          3. More than 4 hours/week exercise habits&#xD;
&#xD;
          4. Immobile, defined as the inability to participate in all study related procedures&#xD;
&#xD;
          5. Dietary intake of fatty fish, fish oils containing omega-3 or pure omega- 3&#xD;
             supplements more than 2 times/week&#xD;
&#xD;
          6. History of complicated gastrointestinal surgery&#xD;
&#xD;
          7. Diagnosed Inflammatory Bowel Disease (IBD)&#xD;
&#xD;
          8. Current diagnosis of psychiatric disease/s or syndromes&#xD;
&#xD;
          9. Systemic use of antibiotics and/or steroid medication in the last 4 months prior to&#xD;
             inclusion time&#xD;
&#xD;
         10. Use of any NSAID (Non-Steroidal Anti-Inflammatory Drugs) more than 3 times a week for&#xD;
             the last 2 months and any time 3 days prior inclusion or at any time 3 days prior the&#xD;
             barrier function test&#xD;
&#xD;
         11. Consumption of any NSAID up until 7 days prior to inclusion&#xD;
&#xD;
         12. Any condition which could interfere with the intestinal barrier function (e.g. gluten&#xD;
             sensitivity, lactose intolerance, celiac disease, IBS, IBD) as decided by the&#xD;
             principal investigators´ discretion&#xD;
&#xD;
         13. Drinking more than 9 standard cups of alcohol per week and/or more than 3 standard&#xD;
             cups of alcohol per occasion.&#xD;
&#xD;
         14. Regular smoking, use of snuff, nicotine or e-cigarette use&#xD;
&#xD;
         15. Regular use, for more than three times a week for the last 2 months and any time 7&#xD;
             days prior to inclusion, of medications which according to the principal investigator&#xD;
             can have an anti-inflammatory effect or affect in any way the intestinal barrier&#xD;
             function or have an impact on the study analysis (e.g. laxatives, anti-diarrheal,&#xD;
             anti-cholinergic).&#xD;
&#xD;
         16. Any disorder which according to the principal investigator can have an&#xD;
             anti-inflammatory effect and/or can affect the intestinal barrier function, or that&#xD;
             can impact an adequate analysis of the study outcomes&#xD;
&#xD;
         17. After being included in the study, starting with a medication/treatment or medical&#xD;
             intervention that could potentially influence the study participation and/or the study&#xD;
             analysis (e.g. the event of a fracture)&#xD;
&#xD;
         18. Radical change in diet (e.g. becoming vegetarian or if they discover that they are&#xD;
             lactose intolerant) during the study period&#xD;
&#xD;
         19. Allergic to fish&#xD;
&#xD;
         20. Allergic to milk- or soy protein&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert JM Brummer, Prof MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Örebro University, Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Örebo University</name>
      <address>
        <city>Örebro</city>
        <zip>703 62</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>October 11, 2019</study_first_submitted>
  <study_first_submitted_qc>October 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 15, 2019</study_first_posted>
  <last_update_submitted>February 23, 2021</last_update_submitted>
  <last_update_submitted_qc>February 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Örebro University, Sweden</investigator_affiliation>
    <investigator_full_name>Robert Brummer</investigator_full_name>
    <investigator_title>Professor of Gastroenterology and Clinical Nutrition, Director Nutrition-Gut-Brain Interactions Research Centre</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

